Lobo Kevin purchased $642K of GEHC

Lobo Kevin purchased 10,000 shares of GE HealthCare Technologies Inc. (GEHC) at $64.18 ($0.64M total) on 2026-05-22.

Original reporting
SEC EDGAR · Lobo Kevin
Published May 26, 2026, 10:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 26, 2026, 10:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GEHC
Bullish
medium confidence
Mentioned
$GEHC
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GEHCBullishMed
01

Why it matters

The market may interpret the purchase as a positive signal, but without earnings, guidance, or deal details the effect is likely sentiment-driven rather than thesis-changing.

02

Market read

A director’s open-market buy in GEHC may provide a small sentiment tailwind, but it is not a standalone fundamental catalyst.

03

What to watch

Check for follow-on insider transactions, volume/price reaction around 2026-05-22, and whether other insiders simultaneously bought/sold.

Relevance 7/10Timing: Immediate (new SEC Form 4 disclosure dated 2026-05-26, covering trade on 2026-05-22).

Background

This is an SEC Form 4 insider transaction disclosure (director open-market purchase) for GE HealthCare Technologies.

Company-level read

Ticker impact

$GEHCBullishMedium confidence
Context

GE HealthCare director Lobo Kevin filed an open-market purchase of 10,000 shares at $64.18 on 2026-05-22.

Expected impact

Likely limited near-term impact; any move may fade unless followed by additional disclosures or fundamentals.

Evidence & confidence

The filing is a director open-market purchase with no 10b5-1 plan and a disclosed post-trade holding, but no new operating information is provided.

Market effects

Minimal; insider activity in one medtech/healthcare name typically does not reset sector expectations without accompanying company-specific news.

None indicated; disclosure is US-listed and does not reference regional operations.

Low; no international deal/regulatory development mentioned.

Counterpoint

Open-market insider buys can be routine (tax/portfolio rebalancing) and may not reflect a new view on near-term fundamentals.

Key entities

  • GE HealthCare Technologies Inc.

    Filed SEC Form 4 showing director Lobo Kevin purchased 10,000 shares on 2026-05-22.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GEHCMed

GE HealthCare adds new capabilities for Vscan Air ultrasound system

GE HealthCare introduced AI-assisted features AutoAS and Lung Guidance for its Vscan Air handheld ultrasound system, cleared by the FDA and CE. These tools aid clinicians in assessing respiratory and cardiac symptoms. AutoAS estimates aortic stenosis severity, while Lung Guidance provides real-time scanning directions. GE HealthCare reported Q3 revenues of $5.5bn, raising its 2026 outlook.

$GEHCHighAI 8/10

What Sent GE HealthCare Stock Higher?

GE HealthCare Technologies (GEHC) stock rose 6.6% after beating Q3 2026 earnings and revenue estimates, with EPS at $1.34 vs. $1.20 and revenue at $5.51B vs. $5.35B. The company reported 6.2% organic revenue growth and raised its full-year outlook. Management noted profit growth outpaced sales, with an adjusted EBIT margin of 16.6%.

$GEHCHighAI 8/10

GE HealthCare raises 2026 outlook after positive Q3

GE HealthCare reported Q3 revenue of $5.5bn, with 7.2% YoY growth, raising its 2026 earnings outlook to $4.95-$5.05 per share. The company's stock opened at $76, up 7% from $71.11. Pharmaceutical diagnostics (PDx) saw the highest growth at 13% YoY, driven by the acquisition of SOFIE Biosciences for $945m, which is expected to enhance radiopharmaceutical offerings.